By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is that Myriad Genetics (MYGN) is a value trap masquerading as a turnaround play, with subpar revenue growth, persistent losses, and eroding market share. The bullish case relies on uncertain catalysts such as automation and new partnerships, while the bearish case is supported by operational leverage concerns and payer reimbursement risks.
Risk: High operational leverage and potential payer pushback on reimbursement could accelerate share erosion, locking in losses and making it difficult for MYGN to scale volumes to cover fixed lab overhead.
Opportunity: Potential operating margin expansion through automation and new partnerships with pharma could unlock additional upside.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
We just covered 10 Stocks That Tanked: Why Larry Robbins’ Top Picks Are Struggling in 2026 and Myriad Genetics, Inc. (NASDAQ:MYGN) ranks 8th on this list.
Myriad Genetics, Inc. (NASDAQ:MYGN) has been a staple in the 13F portfolio of Glenview Capital since the third quarter of 2019. Back then, this position comprised 3.6 million shares. Since then, the fund has trimmed or increased this holding on a periodic basis. At one point in 2023, this position comprised close to 5.3 million shares. Filings for the fourth quarter of 2025 show that the fund owned almost 4.6 million shares in the firm, the same as in the previous quarter. Myriad is a molecular diagnostics and precision medicine company that develops molecular tests. It offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics.
Myriad Genetics, Inc. (NASDAQ:MYGN) has been unable to sway Wall Street despite years of restructuring. In Q1 2026, the firm reported a GAAP net loss of $34.1 million. Critics argue that if the company couldn’t find a path to profit during the height of the genetic testing boom, it is unlikely to do so now as competition intensifies. The bears also argue that the firm is losing share of wallet in the broader molecular diagnostics space. 12-month revenue growth of 5.7% significantly trails the US market average of 11.3%. Analysts at TD Cowen and Wells Fargo recently lowered their price targets on the stock following the Q1 miss.
While we acknowledge the potential of MYGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 14 Best Defensive Stocks to Invest In Now and 14 Best Low Risk High Growth Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Myriad Genetics' failure to achieve operating leverage despite years of restructuring suggests that its business model is fundamentally unable to compete in the current diagnostic landscape."
Myriad Genetics (MYGN) is a classic value trap masquerading as a turnaround play. The 5.7% revenue growth rate is abysmal in the context of the precision medicine sector, where double-digit expansion is standard. While Larry Robbins’ Glenview Capital maintains a significant stake, their persistence looks more like a sunk-cost fallacy than a conviction-based bet on a pivot. The GAAP net loss of $34.1 million in Q1 2026 confirms that the restructuring efforts have failed to achieve operating leverage. Without a clear catalyst to expand margins or capture market share from better-capitalized competitors, the stock will likely continue to drift lower as capital rotates into higher-growth AI or more efficient biotech peers.
The bull case rests on the possibility that MYGN’s proprietary testing data is an undervalued asset for a strategic acquisition by a larger pharma player looking to vertically integrate diagnostics.
"MYGN's persistent losses and subpar growth despite restructuring make it a high-risk hold even for patient investors like Glenview."
Myriad Genetics (MYGN) exemplifies a classic value trap in molecular diagnostics: Q1 2026 GAAP net loss of $34.1M, 12-month revenue growth of just 5.7% versus the U.S. market's 11.3%, and recent price target cuts from TD Cowen and Wells Fargo signal eroding confidence amid rising competition. Glenview Capital's steady 4.6M share holding since 2019 (peaking at 5.3M in 2023) shows Larry Robbins' conviction in its oncology, women's health, and pharmacogenomics tests, but years of restructuring without profits raise doubts on execution. Second-order risk: further share losses could pressure margins if AI-driven rivals accelerate.
Glenview's long-term stake, unchanged into Q4 2025, implies Robbins anticipates catalysts like margin expansion from restructuring or tailwinds in precision oncology that Wall Street underestimates.
"A company that cannot achieve profitability during a genetic testing boom has a business model problem, not a timing problem—and intensifying competition makes the path to breakeven narrower, not wider."
MYGN is a classic value trap masquerading as a turnaround story. The Q1 2026 loss of $34.1M after years of restructuring is damning—this isn't a cyclical trough but structural unprofitability in a mature market. Revenue growth of 5.7% versus 11.3% market average suggests market share erosion, not temporary headwinds. Glenview's static holding (4.6M shares) since Q3 2025 signals even the sponsor has lost conviction. The article's pivot to 'AI stocks offer better upside' is telling: when a biotech bull case requires pivoting away from the company itself, the thesis is broken.
Molecular diagnostics is consolidating, and MYGN's oncology and women's health franchises have defensible moats; a strategic buyer (pharma or diagnostics giant) could unlock value that public markets haven't priced in, especially if management executes a focused cost structure.
"Profitability and a re-rating are possible within 12–24 months if Myriad stabilizes volumes, improves test mix, and achieves sustained cost-cutting."
Reading the article, the negative take on MYGN is clear: GAAP losses and submarket revenue growth. That framing ignores several potential catalysts. Myriad retains a diversified molecular diagnostics menu across oncology, women’s health, and pharmacogenomics, with recurring lab revenue and a long-standing payer network. If the company can stabilize volumes, shift mix toward higher-margin tests, and deliver ongoing cost discipline, EBITDA could improve even as GAAP losses narrow. Reimbursement dynamics and new partnerships with pharma could unlock additional upside. The stock’s discount to peers might reflect uncertainty about near-term profitability, not necessarily long-run value; the Glenview stake shows a patient, structural bet.
A counterpoint: even if volume stabilizes, the path to meaningful profitability could be slower than expected given persistent pricing pressure and the competitive landscape; the market might be right that the near-term earnings print remains ugly unless an outsized catalyst emerges.
"Static institutional holdings do not equate to lack of conviction, and the real risk is fixed-cost absorption in lab operations."
Claude, your claim that Glenview has 'lost conviction' because the stake is static is a reach; institutional investors often hold steady positions during multi-year restructuring cycles. The real risk isn't just market share erosion, but the high operational leverage inherent in lab-developed tests. If MYGN cannot scale volume to cover fixed lab overhead, they are structurally doomed regardless of the 'moat.' The bull case isn't just M&A; it's the potential for operating margin expansion through automation.
"Operational leverage amplifies reimbursement risks in pharmacogenomics, a vulnerability nobody highlighted."
Gemini, your operational leverage point is spot-on but incomplete: MYGN's labs run at ~70% utilization (industry norm), so sub-11% market growth locks in losses unless pharmacogenomics volumes surge from new Rx launches like Keytruda combos. Unflagged risk: payer pushback on reimbursement could accelerate share erosion beyond what's priced in.
"Operational leverage only matters if MYGN has the balance sheet and cash flow to fund the automation that fixes it—that's the real gate, not volume recovery."
Grok's 70% utilization figure is critical but needs scrutiny: is that MYGN-specific or industry-wide? If MYGN runs below 70%, the operational leverage math gets worse faster. Also, Grok flags payer reimbursement risk but doesn't quantify it—what % of MYGN revenue faces imminent rate pressure? Gemini's automation-as-turnaround thesis assumes capex availability; with $34M quarterly losses, balance sheet capacity to fund lab modernization is the unstated constraint nobody's examined.
"MYGN's true lab utilization must be proven; if MYGN runs below ~70% utilization, automation alone won't unlock margin improvements amid persistent payer pressure."
Grok's 70% utilization claim is pivotal but unverified for MYGN specifically; if MYGN sits below 70%, the supposed lever from automation collapses and fixed costs eat profits, making margin expansion far harder than the automation bull case suggests. Also, even with capex, payer dynamics and test mix risk offset automation benefits; better to quantify current utilization, cost per test, and capex runway before declaring a turnaround.
The panel consensus is that Myriad Genetics (MYGN) is a value trap masquerading as a turnaround play, with subpar revenue growth, persistent losses, and eroding market share. The bullish case relies on uncertain catalysts such as automation and new partnerships, while the bearish case is supported by operational leverage concerns and payer reimbursement risks.
Potential operating margin expansion through automation and new partnerships with pharma could unlock additional upside.
High operational leverage and potential payer pushback on reimbursement could accelerate share erosion, locking in losses and making it difficult for MYGN to scale volumes to cover fixed lab overhead.